West Pharmaceutical Servs informa las ganancias trimestralmente. Estos informes de ganancias trimestrales ofrecen a los inversores una visión de los resultados financieros de una empresa durante un período de 3 meses. Los informes de ganancias casi siempre incluyen resultados de EPS e ingresos.
Analice el historial de beneficios de West Pharmaceutical Servs utilizando filtros y clasificaciones avanzadas.
Get Alert | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
WST | West Pharmaceutical Servs | $1.85 | $1.68 | $1.96 | 16.67% | $746.90M | $786.83M | $804.60M | 2.26% | 10/23/2025 | |
WST | West Pharmaceutical Servs | $1.52 | $1.51 | $1.84 | 21.85% | $702.10M | $726.62M | $766.50M | 5.49% | 07/24/2025 | |
WST | West Pharmaceutical Servs | $1.56 | $1.23 | $1.45 | 17.89% | $695.40M | $685.83M | $698.00M | 1.77% | 04/24/2025 | |
WST | West Pharmaceutical Servs | $1.83 | $1.73 | $1.82 | 5.20% | $732.00M | $740.87M | $748.80M | 1.07% | 02/13/2025 | |
WST | West Pharmaceutical Servs | $2.16 | $1.50 | $1.85 | 23.33% | $747.40M | $709.62M | $746.90M | 5.25% | 10/24/2024 | |
WST | West Pharmaceutical Servs | $2.11 | $1.74 | $1.52 | -12.64% | $753.80M | $729.35M | $702.10M | -3.74% | 07/25/2024 | |
WST | West Pharmaceutical Servs | $1.98 | $1.26 | $1.56 | 23.81% | $716.60M | $670.30M | $695.40M | 3.74% | 04/25/2024 | |
WST | West Pharmaceutical Servs | $1.77 | $1.78 | $1.83 | 2.81% | $708.70M | $739.47M | $732.00M | -1.01% | 02/15/2024 | |
WST | West Pharmaceutical Servs | $2.03 | $1.86 | $2.16 | 16.13% | $686.90M | $750.31M | $747.40M | -0.39% | 10/26/2023 | |
WST | West Pharmaceutical Servs | $2.47 | $1.93 | $2.11 | 9.33% | $771.30M | $756.53M | $753.80M | -0.36% | 07/27/2023 | |
WST | West Pharmaceutical Servs | $2.30 | $1.65 | $1.98 | 20.00% | $720.00M | $693.82M | $716.60M | 3.28% | 04/27/2023 | |
WST | West Pharmaceutical Servs | $2.04 | $1.38 | $1.77 | 28.26% | $730.80M | $657.17M | $708.70M | 7.84% | 02/16/2023 | |
WST | West Pharmaceutical Servs | $2.06 | $2.12 | $2.03 | -4.25% | $706.50M | $731.61M | $686.90M | -6.11% | 10/27/2022 | |
WST | West Pharmaceutical Servs | $2.46 | $2.21 | $2.47 | 11.76% | $723.60M | $755.57M | $771.30M | 2.08% | 07/28/2022 | |
WST | West Pharmaceutical Servs | $2.05 | $2.12 | $2.30 | 8.49% | $670.70M | $720.92M | $720.00M | -0.13% | 04/28/2022 | |
WST | West Pharmaceutical Servs | $1.34 | $1.91 | $2.04 | 6.81% | $580.20M | $710.20M | $730.80M | 2.90% | 02/17/2022 | |
WST | West Pharmaceutical Servs | $1.15 | $1.80 | $2.06 | 14.44% | $548.00M | $687.09M | $706.50M | 2.82% | 10/28/2021 | |
WST | West Pharmaceutical Servs | $1.25 | $1.74 | $2.46 | 41.38% | $527.20M | $669.38M | $723.60M | 8.10% | 07/29/2021 | |
WST | West Pharmaceutical Servs | $1.01 | $1.43 | $2.05 | 43.36% | $491.50M | $611.39M | $670.70M | 9.70% | 04/29/2021 | |
WST | West Pharmaceutical Servs | $0.82 | $1.12 | $1.34 | 19.64% | $470.60M | $543.67M | $580.20M | 6.72% | 02/18/2021 |
| Trimestre Fiscal | Fecha reportada | EPS real | EPS estimado | Sorpresa % |
|---|---|---|---|---|
| Q3 | 2025-10-23 | $1.96 | $1.68 | 16.7 % |
| Q2 | 2025-07-24 | $1.84 | $1.51 | 21.9 % |
| Q1 | 2025-04-24 | $1.45 | $1.23 | 17.9 % |
| Q4 | 2025-02-13 | $1.82 | $1.73 | 5.20 % |
| Trimestre Fiscal | Fecha reportada | Ingresos reales | Ingresos estimados | Sorpresa % |
|---|---|---|---|---|
| Q3 | 2025-10-23 | $804.60M | $786.83M | 2.26 % |
| Q2 | 2025-07-24 | $766.50M | $726.62M | 5.49 % |
| Q1 | 2025-04-24 | $698.00M | $685.83M | 1.77 % |
| Q4 | 2025-02-13 | $748.80M | $740.87M | 1.07 % |
West Pharmaceutical Servs (WST) aún no tiene ningún informe de resultados previsto. El último informe de resultados se publicó el octubre 23, 2025 para el Q3.
West Pharmaceutical Servs (WST) aún no tiene ningún informe de resultados previsto. El último informe de resultados se publicó el octubre 23, 2025 para el Q3 y el BPA real fue de $1.96, que superó la estimación de $1.68.
West Pharmaceutical Servs (WST) aún no tiene ningún informe de resultados previsto. El último informe de resultados se publicó el octubre 23, 2025 para el Q3 y los ingresos reales fueron de $804.6M, que superó la estimación de $786.8M.
Explora Estimaciones de beneficios, BPA e ingresos sobre todos los valores.